title: The impact of steady-state cyclosporine concentrations on renal allograft outcome.
abstract: It has been reported that initial cyclosporine levels over 400 ng/ml posttransplantation result in an increased incidence of delayed graft function (DGF). Several studies have shown early graft function to be a major determinant for long-term graft survival. Continuous intravenous infusion (CIVI) has been employed to induce immunosuppression establishing therapeutic drug levels while minimizing toxicity in renal allograft recipients. This study examines the impact of the achieved serum CsA steady-state concentration (Css) levels upon transplant outcome in 228 patients given CsA by CIVI. In spite of administration of a specific drug dose, interindividual variation in elimination rates yields a broad range of Css levels. Six groups were stratified by CsA Css levels: group A 0-75 ng/ml, group B 76-100 ng/ml, group C 101-150 ng/ml, group D 151-200 ng/ml, group E 201-250 ng/ml, and group F greater than 250 ng/ml. Group A showed a significantly lower age and greater incidence of rejection at 0-10 days. Group F had significantly higher incidences of nephrotoxicity, hepatotoxicity, and delayed graft function. The findings suggest that the antirejection Css threshold for CsA may be at least 75 ng/ml, and the toxicity threshold above 250 ng/ml. Controversy exists about whether CsA influences the incidence of DGF, therefore risk factors for DGF were examined among the groups stratified by CsA Css levels. While cold ischemia time for all 228 patients as a group was highly correlated with DGF (P less than 0.001), neither cold ischemia time nor donor age was significantly different among the groups. There does appear to be a synergistic effect between CsA Css and CIT, since the incidence of DGF was significantly higher when the cold ischemia time was 21-24 hr and CsA Css greater than 200 ng/ml. Long-term graft function did not appear to be affected by early CsA Css levels. The Css of 100-250 ng/ml appears to achieve a satisfactory outcome with a 19.5% incidence of rejection within 10 days, 29.7% DGF, and 5.1% nephrotoxicity. Only 118/228 patients (52%) in this study achieved that range despite a fixed low CIVI of CsA. Thus potential renal allograft recipients may benefit from a pretransplant pharmacokinetic study to predict the proper CIVI dose.
authors.affiliation: Department of Surgery, University of Texas Medical School, Houston 77030.
authors.forename: J
authors.initials: J
authors.lastname: Dunn
authors.forename: J
authors.initials: J
authors.lastname: Grevel
authors.forename: K
authors.initials: K
authors.lastname: Napoli
authors.forename: R M
authors.initials: RM
authors.lastname: Lewis
authors.forename: C T
authors.initials: CT
authors.lastname: Van Buren
authors.forename: B D
authors.initials: BD
authors.lastname: Kahan
mesh_terms: D000328:Adult; D003524:Cyclosporins / Q000008:administration & dosage* / Q000009:adverse effects; D006084:Graft Rejection; D006801:Humans; D007262:Infusions, Intravenous; D007511:Ischemia / Q000150:complications; D007668:Kidney / Q000187:drug effects; D016030:Kidney Transplantation; D008099:Liver / Q000187:drug effects; D014184:Transplantation, Homologous
chemical_list: D003524:Cyclosporins